Fate Operating Income vs Cost Of Revenue Analysis

FATE Stock

USD 3.90 0.24 5.80%

Fate Therapeutics financial indicator trend analysis is much more than just examining Fate Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fate Therapeutics is a good investment. Please check the relationship between Fate Therapeutics Operating Income and its Cost Of Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

Operating Income vs Cost Of Revenue

Operating Income vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fate Therapeutics Operating Income account and Cost Of Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Fate Therapeutics' Operating Income and Cost Of Revenue is -0.01. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Fate Therapeutics, assuming nothing else is changed. The correlation between historical values of Fate Therapeutics' Operating Income and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Fate Therapeutics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Operating Income i.e., Fate Therapeutics' Operating Income and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Fate Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Fate Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Fate Therapeutics income statement and represents the costs associated with goods and services Fate Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Fate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Issuance Of Capital Stock is projected to grow to (26.5 K).

	2021	2022	2023	2024 (projected)
Interest Expense	4.5M	5.8M	6.7M	7.1M
Depreciation And Amortization	1.3M	13.8M	18.3M	19.2M

Interest Expense Depreciation And Amortization

Fate Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.9	0.95	0.93	0.99	0.72	0.61	0.77	0.24	-0.77	0.93	0.48	0.93	0.82	0.59	0.46	0.99	0.81	0.92	0.86	0.72	0.85	0.93	0.56	-0.45	0.99
Short Long Term Debt Total	0.9		0.87	0.85	0.88	0.55	0.87	0.63	0.52	-0.93	0.8	0.25	0.96	0.65	0.5	0.46	0.88	0.88	0.86	0.82	0.82	0.96	0.87	0.83	-0.43	0.89
Other Current Liab	0.95	0.87		0.98	0.91	0.69	0.57	0.87	0.23	-0.74	0.91	0.47	0.85	0.8	0.73	0.42	0.94	0.77	0.88	0.86	0.77	0.8	0.95	0.53	-0.39	0.96
Total Current Liabilities	0.93	0.85	0.98		0.9	0.64	0.51	0.93	0.23	-0.72	0.9	0.45	0.83	0.87	0.67	0.4	0.92	0.74	0.85	0.81	0.81	0.79	0.93	0.46	-0.41	0.94
Total Stockholder Equity	0.99	0.88	0.91	0.9		0.68	0.61	0.74	0.19	-0.77	0.91	0.52	0.93	0.8	0.51	0.5	0.98	0.84	0.93	0.79	0.71	0.86	0.87	0.55	-0.54	0.98
Other Liab	0.72	0.55	0.69	0.64	0.68		0.24	0.5	-0.18	-0.26	0.62	0.67	0.56	0.49	0.84	0.28	0.78	0.44	0.55	0.77	0.12	0.4	0.75	0.23	-0.26	0.75
Property Plant And Equipment Net	0.61	0.87	0.57	0.51	0.61	0.24		0.21	0.63	-0.94	0.53	0.0	0.79	0.24	0.2	0.31	0.58	0.83	0.68	0.57	0.7	0.9	0.57	0.99	-0.33	0.59
Current Deferred Revenue	0.77	0.63	0.87	0.93	0.74	0.5	0.21		0.13	-0.48	0.77	0.39	0.63	0.92	0.59	0.31	0.76	0.48	0.66	0.65	0.73	0.55	0.8	0.14	-0.31	0.79
Net Debt	0.24	0.52	0.23	0.23	0.19	-0.18	0.63	0.13		-0.57	0.2	-0.7	0.5	0.25	-0.1	-0.05	0.13	0.23	0.17	0.39	0.56	0.49	0.34	0.6	0.22	0.16
Retained Earnings	-0.77	-0.93	-0.74	-0.72	-0.77	-0.26	-0.94	-0.48	-0.57		-0.71	-0.13	-0.88	-0.5	-0.24	-0.42	-0.73	-0.92	-0.84	-0.62	-0.88	-0.98	-0.69	-0.91	0.45	-0.75
Accounts Payable	0.93	0.8	0.91	0.9	0.91	0.62	0.53	0.77	0.2	-0.71		0.44	0.86	0.81	0.52	0.4	0.92	0.75	0.88	0.82	0.73	0.78	0.9	0.48	-0.26	0.92
Cash	0.48	0.25	0.47	0.45	0.52	0.67	0.0	0.39	-0.7	-0.13	0.44		0.23	0.27	0.54	0.44	0.58	0.47	0.53	0.25	0.05	0.25	0.35	0.0	-0.61	0.56
Non Current Assets Total	0.93	0.96	0.85	0.83	0.93	0.56	0.79	0.63	0.5	-0.88	0.86	0.23		0.75	0.39	0.38	0.9	0.84	0.85	0.82	0.78	0.94	0.87	0.73	-0.37	0.91
Non Currrent Assets Other	0.82	0.65	0.8	0.87	0.8	0.49	0.24	0.92	0.25	-0.5	0.81	0.27	0.75		0.4	0.27	0.78	0.47	0.65	0.68	0.7	0.59	0.8	0.15	-0.23	0.81
Other Assets	0.59	0.5	0.73	0.67	0.51	0.84	0.2	0.59	-0.1	-0.24	0.52	0.54	0.39	0.4		0.23	0.65	0.36	0.47	0.7	0.22	0.32	0.72	0.22	-0.2	0.64
Long Term Debt	0.46	0.46	0.42	0.4	0.5	0.28	0.31	0.31	-0.05	-0.42	0.4	0.44	0.38	0.27	0.23		0.48	0.56	0.62	0.27	0.35	0.45	0.34	0.3	-0.59	0.48
Cash And Short Term Investments	0.99	0.88	0.94	0.92	0.98	0.78	0.58	0.76	0.13	-0.73	0.92	0.58	0.9	0.78	0.65	0.48		0.82	0.92	0.84	0.66	0.83	0.92	0.54	-0.5	1.0
Common Stock Total Equity	0.81	0.88	0.77	0.74	0.84	0.44	0.83	0.48	0.23	-0.92	0.75	0.47	0.84	0.47	0.36	0.56	0.82		0.92	0.56	0.76	0.95	0.67	0.81	-0.67	0.82
Common Stock Shares Outstanding	0.92	0.86	0.88	0.85	0.93	0.55	0.68	0.66	0.17	-0.84	0.88	0.53	0.85	0.65	0.47	0.62	0.92	0.92		0.71	0.76	0.88	0.81	0.64	-0.57	0.92
Non Current Liabilities Total	0.86	0.82	0.86	0.81	0.79	0.77	0.57	0.65	0.39	-0.62	0.82	0.25	0.82	0.68	0.7	0.27	0.84	0.56	0.71		0.55	0.68	0.97	0.53	-0.01	0.84
Other Current Assets	0.72	0.82	0.77	0.81	0.71	0.12	0.7	0.73	0.56	-0.88	0.73	0.05	0.78	0.7	0.22	0.35	0.66	0.76	0.76	0.55		0.87	0.69	0.65	-0.35	0.7
Other Stockholder Equity	0.85	0.96	0.8	0.79	0.86	0.4	0.9	0.55	0.49	-0.98	0.78	0.25	0.94	0.59	0.32	0.45	0.83	0.95	0.88	0.68	0.87		0.76	0.86	-0.51	0.84
Total Liab	0.93	0.87	0.95	0.93	0.87	0.75	0.57	0.8	0.34	-0.69	0.9	0.35	0.87	0.8	0.72	0.34	0.92	0.67	0.81	0.97	0.69	0.76		0.53	-0.18	0.93
Property Plant And Equipment Gross	0.56	0.83	0.53	0.46	0.55	0.23	0.99	0.14	0.6	-0.91	0.48	0.0	0.73	0.15	0.22	0.3	0.54	0.81	0.64	0.53	0.65	0.86	0.53		-0.32	0.54
Preferred Stock Total Equity	-0.45	-0.43	-0.39	-0.41	-0.54	-0.26	-0.33	-0.31	0.22	0.45	-0.26	-0.61	-0.37	-0.23	-0.2	-0.59	-0.5	-0.67	-0.57	-0.01	-0.35	-0.51	-0.18	-0.32		-0.49
Total Current Assets	0.99	0.89	0.96	0.94	0.98	0.75	0.59	0.79	0.16	-0.75	0.92	0.56	0.91	0.81	0.64	0.48	1.0	0.82	0.92	0.84	0.7	0.84	0.93	0.54	-0.49

Click cells to compare fundamentals

Fate Therapeutics Account Relationship Matchups

Fate Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	302.3M	622.5M	921.5M	705.6M	506.2M	310.1M
Short Long Term Debt Total	26.9M	97.3M	114.8M	109.3M	103.5M	108.7M
Other Current Liab	17.5M	54.8M	45.6M	57.9M	27.5M	18.9M
Total Current Liabilities	27.8M	85.6M	81.3M	114.1M	39.1M	36.6M
Total Stockholder Equity	244.8M	384.4M	678.8M	483.9M	368.4M	210.3M
Other Liab	4.5M	58.5M	52.1M	3.9M	4.4M	4.2M
Property Plant And Equipment Net	22.8M	67.1M	70.7M	66.1M	158.5M	166.4M
Current Deferred Revenue	2.8M	21.1M	21.5M	42.2M	685K	650.8K
Net Debt	(72.9M)	(70.0M)	(18.8M)	48.0M	61.7M	64.7M
Retained Earnings	(383.5M)	(556.9M)	(769.1M)	(1.1B)	(1.2B)	(1.2B)
Accounts Payable	5.8M	6.3M	8.6M	8.3M	4.7M	4.0M
Cash	99.8M	167.3M	133.6M	61.3M	41.9M	39.8M
Non Current Assets Total	75.2M	128.1M	288.0M	203.5M	174.7M	183.4M
Non Currrent Assets Other	13.0M	32.3M	116.7M	132.5M	9.0K	8.5K
Other Assets	1.6M	95.8M	25.1M	22.5M	1.0	0.95
Cash And Short Term Investments	221.4M	482.9M	615.9M	436.2M	315.2M	224.2M
Common Stock Total Equity	65K	76K	88K	96K	110.4K	115.9K
Common Stock Shares Outstanding	68.2M	82.4M	94.7M	96.8M	98.4M	54.2M
Liabilities And Stockholders Equity	302.3M	622.5M	921.5M	705.6M	506.2M	310.1M
Non Current Liabilities Total	29.7M	152.4M	161.3M	107.6M	98.7M	63.3M
Other Current Assets	4.3M	5.9M	8.8M	27.4M	13.6M	14.3M
Other Stockholder Equity	628.2M	941.2M	1.4B	1.5B	1.6B	1.7B
Total Liab	57.5M	238.0M	242.6M	221.6M	137.8M	99.9M
Property Plant And Equipment Gross	34.2M	99.4M	70.7M	66.1M	206.1M	216.4M
Total Current Assets	227.1M	494.3M	633.4M	502.1M	331.5M	234.9M
Accumulated Other Comprehensive Income	22K	70K	(762K)	(1.9M)	15K	15.8K
Short Term Debt	1.7M	3.4M	5.6M	5.6M	6.2M	4.6M
Common Stock	76K	88K	96K	97K	99K	58.1K
Property Plant Equipment	11.4M	32.3M	162.2M	176.1M	202.5M	212.6M
Net Tangible Assets	274.5M	536.9M	678.8M	483.9M	556.5M	584.4M
Retained Earnings Total Equity	(285.4M)	(383.5M)	(556.9M)	(769.1M)	(692.2M)	(657.6M)
Short Term Investments	121.6M	315.6M	482.3M	374.9M	273.3M	159.4M
Capital Surpluse	445.8M	628.2M	941.2M	1.4B	1.7B	1.7B
Deferred Long Term Liab	1.3M	13.5M	9.9M	7.2M	8.3M	5.0M
Non Current Liabilities Other	175K	549K	702K	800K	920K	721.9K
Net Invested Capital	244.8M	384.4M	678.8M	483.9M	368.4M	381.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VWITX	Vanguard Intermediate Term Tax Exempt
VGSTX	Vanguard Star Fund
VFIAX	Vanguard 500 Index

When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:

How To Invest In Fate

Details

Is Fate Stock a good investment?

Details

What is Fate Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Fate Stock analysis

When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Equity Valuation Check real value of public entities based on technical and fundamental data

Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.92)

Revenue Per Share

0.065

Quarterly Revenue Growth

(0.97)

Return On Assets

(0.21)

Return On Equity

(0.42)

The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fate Operating Income vs Cost Of Revenue Analysis

Operating Income vs Cost Of Revenue

Operating Income vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Operating Income

Cost Of Revenue

Fate Therapeutics fundamental ratios Correlations

Fate Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fate Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Fate Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Current Liabilities	+ 0.98	Other Current Liab

Other Stockholder Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.94	Property Plant And Equipment Net
Retained Earnings	- 0.93	Short Long Term Debt Total
Common Stock Total Equity	- 0.92	Retained Earnings
Property Plant And Equipment Gross	- 0.91	Retained Earnings
Other Current Assets	- 0.88	Retained Earnings